scholarly journals Plasma Arginase-1 Level Is Associated with the Mental Status of Outpatients with Chronic Liver Disease

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 317
Author(s):  
Noriyoshi Ogino ◽  
Fusao Ikeda ◽  
Shihoko Namba ◽  
Shinnosuke Ohkubo ◽  
Tomoaki Nishimura ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Regression Analysis ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Mental Status ◽  
Logistic Regression Analysis ◽  
General Health Questionnaire ◽  
Chronic Liver ◽  
University Hospital ◽  
Arginase 1

While plasma arginase-1 has been suggested as a biomarker of mental status in healthy individuals, it has not been evaluated in patients with chronic liver disease. This cross-sectional study investigated the utility of plasma arginase-1 for screening mental status in patients with chronic liver disease. This study included outpatients with chronic liver disease who underwent regular check-ups at Okayama University Hospital between September 2018 and January 2019. In addition to the standard blood tests, the plasma arginase-1 level was analyzed. The patients’ mental status was assessed using the Japanese version of the General Health Questionnaire-28 (GHQ-28). The associations between mental status and various parameters, including plasma arginase-1, were investigated using logistic regression analysis. Among 114 participating patients, 8 were excluded, comprising 6 with insufficient blood samples for plasma arginase-1 measurement and 2 with incomplete questionnaires. Multivariate binomial logistic regression analysis revealed that plasma arginase-1 was significantly and negatively associated with the GHQ-total score, especially somatic symptoms. Therefore, plasma arginase-1 may be a useful biomarker for assessing the mental status of outpatients with chronic liver disease.

scholarly journals Comorbidity Risk Factors Contributing to COVID-19 Related Deaths in Florida, March 1, 2020-January 16, 2021

2021 ◽  
Author(s):  
Ursula K Weiss ◽  
Jason D Maynard ◽  
Katherine McDaniel ◽  
Alyssa Cohen ◽  
Marie Bailey ◽  
...  
Keyword(s):  
Risk Factors ◽  
Logistic Regression ◽  
Down Syndrome ◽  
Heart Disease ◽  
Liver Disease ◽  
Kidney Disease ◽  
Chronic Liver Disease ◽  
Causes Of Death ◽  
Chronic Liver ◽  
Comorbid Conditions

Abstract Objectives To assess the association of specific comorbid conditions to COVID-19 deaths in Florida among decedents 16 to 64 years of age. Methods This report uses Florida vital statistics death data over the period of March 1, 2020 through January 16, 2021, to estimate the effects of comorbid conditions on COVID-19 mortality for decedents 16 to 64 years of age. All cases of COVID-19 death occurring in Florida, regardless of resident status, were evaluated. The comorbidities, or contributing causes of death, identified in this report include Down syndrome, asthma, diabetes, pulmonary fibrosis, obesity, dementia, immunodeficiency, kidney disease, chronic obstructive pulmonary disease, hypertension, heart disease, and chronic liver disease and cirrhosis. The study uses a binary logistic regression to examine the relationship between COVID-19 and non-COVID-19 death and contributing causes of death based on information in the death record. Odds ratios were calculated as a residual of the logistic regression. Results Among COVID-19 deaths, Down syndrome was 15.26 times more likely to be a contributing cause of death compared to non-COVID-19 deaths followed by asthma (OR 7.74), diabetes (OR 6.11), pulmonary fibrosis (OR 5.13), obesity (OR 4.66), dementia (OR 4.51), immunodeficiency (OR 2.49), and kidney disease (OR 2.13). Chronic liver disease and cirrhosis (OR 0.95) and cancer (OR 0.79) had lower odds of being a contributing cause of death. Conclusions Heart disease, chronic liver disease and cirrhosis, and cancer were not risk factors for death from COVID-19 among decedents. Additional studies are needed to elucidate associations between race/ethnicity, socioeconomic status, and behavioral factors.

scholarly journals Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e039947
Author(s):  
Atsushi Takahashi ◽  
Yukio Anzai ◽  
Masahito Kuroda ◽  
Masae Kokubun ◽  
Yuichiro Kondo ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Regression Analysis ◽  
Liver Disease ◽  
Sleep Quality ◽  
Fatty Liver ◽  
Logistic Regression Analysis ◽  
Fatty Liver Disease ◽  
Medication Use ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

BackgroundThe effects of sleep quality on the risk of developing non-alcoholic fatty liver disease (NAFLD) remain uncertain. The purpose of this study was to clarify the association between sleep quality and NAFLD.MethodsThe data of 4828 participants who underwent health check-ups at four hospitals were analysed. Sleep quality was evaluated by the Pittsburgh Sleep Quality Index (PSQI), which comprised seven elements scored from 0 to 3. The global PSQI score and the score for each element were compared between NAFLD and non-NAFLD groups separately by sex. Logistic regression analysis was performed to determine the association between NAFLD and each PSQI score.ResultsIn both men and women, the mean PSQI score for sleep medication use was significantly higher in non-NAFLD than in NAFLD. With regard to sleep medication use in men, the OR (95% CI) for NAFLD was lower with a score of 3 (OR 0.60, 95% CI 0.38–0.95) than with a score of 0 on multivariate logistic regression analysis adjusted for age, smoking habits and physical activity. The OR for NAFLD based on daytime dysfunction was also higher with a score of 3 than with a score of 0 in both men (OR 2.82, 95% CI 1.39–5.75) and women (OR 2.08, 95% CI 1.10–3.92). After adjustment for body mass index, the sleep latency scores in men and daytime dysfunction in women were associated with NAFLD.ConclusionSleep quality was associated with NAFLD, and there were sex differences.

Rhabdomyolysis Associated with Gemfibrozil—Colchicine Therapy

2002 ◽  
Vol 36 (11) ◽  
pp. 1719-1721 ◽  
Author(s):  
Hulusi Atmaca ◽  
Hayriye Sayarlıoğlu ◽  
Eyüp Külah ◽  
Nejat Demircan ◽  
Tekin Akpolat
Keyword(s):  
Liver Disease ◽  
Hepatitis B ◽  
Combination Therapy ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
University Hospital ◽  
Drug Event ◽  
Case Summary ◽  
B Virus ◽  
The University

OBJECTIVE: To report a case of rhabdomyolysis possibly due to combination therapy with colchicine and gemfibrozil. CASE SUMMARY: A 40-year-old man with amyloidosis and hepatitis B virus—related chronic liver disease was admitted to the university hospital because of fatigue, lack of appetite, dark brownish urine, and myalgia for 2 weeks. The patient was receiving colchicine and gemfibrozil. Elevations of serum creatine kinase, lactate dehydrogenase, and aspartate aminotransferase concentrations with myalgia were compatible with the diagnosis of rhabdomyolysis. DISCUSSION: To our knowledge, myopathy and rhabdomyolysis due to a combination of colchicine and gemfibrozil therapy have not been previously reported. Preexisting mild renal failure, hepatitis B—related chronic liver disease, and amyloidosis may be contributing risk factors for the development of rhabdomyolysis in this patient. An objective causality assessment revealed that the adverse drug event was possible. CONCLUSIONS: Patients receiving combination therapy with colchicine and gemfibrozil, especially those with renal and hepatic dysfunction, should be monitored for rhabdomyolysis, and concomitant colchicine and gemfibrozil therapy should be considered in the differential diagnosis of rhabdomyolysis.

scholarly journals Medication Non-adherence Prevalence and Determinants in Children and Adolescents with Chronic Liver Diseases

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Seyed Mohsen Dehghani ◽  
Alireza Shamsaeefar ◽  
Azar Kazemi ◽  
Kourosh Kazemi ◽  
Amirali Mashhadiagha ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Liver Disease ◽  
Medication Adherence ◽  
Chronic Liver Disease ◽  
Liver Diseases ◽  
Underlying Disease ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Housing Status ◽  
Adherence Scale

Background: Medication adherence is one of the most important challenges in chronic diseases. Objectives: In this study, we investigated medication adherence prevalence among children with chronic liver diseases. Methods: A total of 160 children with chronic liver disease were enrolled in our study. We evaluated medication adherence using the 8-item Morisky Medication Adherence Scale (MMAS-8) and classified them based on the scores (score < 6 = low adherence, scores 6 - 8 = medium adherence, and > 8 = high adherence). Logistic regression recognized final influencing variables on adherence. Results: Of 160 patients, 84 (52.5%) were female, and the mean age of patients was 11.2 ± 4.4 years. Also, 56 participants (35%) were high adherers, and 66 (41.25%) were low adherers. The most common reason for low adherence was forgetfulness in 37 patients (23.13%) and low access to medication in 21 subjects (13.13%). In multivariate logistic regression, age, housing status, and underlying disease were significantly associated with medication adherence. Conclusions: Almost half of the children with liver cirrhosis demonstrated low medication adherence. Age, housing status, and underlying disease were significantly associated with medication adherence. We should implement programs to reduce medication non-adherence among children with chronic liver disease.

scholarly journals Risk Factors for Orbital Implant Extrusion after Evisceration

2021 ◽  
Vol 10 (15) ◽  
pp. 3329
Author(s):  
Ju-Mi Kim ◽  
Jae-Yun Sung ◽  
Hyung-Bin Lim ◽  
Eun-Jung Choi ◽  
Sung-Bok Lee
Keyword(s):  
Risk Factors ◽  
Logistic Regression ◽  
Regression Analysis ◽  
Logistic Regression Analysis ◽  
Multiple Logistic Regression Analysis ◽  
Orbital Cellulitis ◽  
University Hospital ◽  
Endogenous Endophthalmitis ◽  
National University ◽  
Implant Size

This study analyzed risk factors for extrusion of orbital implants after evisceration by comparing patients with and without implant extrusion. Methods: We retrospectively reviewed the medical records of patients who underwent evisceration with primary implant placement by a single surgeon from January 2005 to December 2019 at the Chungnam National University Hospital. Age, sex, underlying systemic diseases, axial length of the fellow eye, the cause of evisceration, endophthalmitis type, implant type and size, and preoperative computed tomography findings were evaluated. Logistic regression analysis was used to identify the risk factors for implant extrusion. Results: Of the 140 eyes of 140 patients, extrusion occurred in five eyes (3.6%). Endophthalmitis (odds ratio (OR), 15.49; 95% confidence interval (CI), 1.70 to 2038.56; p = 0.010), endogenous endophthalmitis (OR, 18.73; 95% CI, 3.22 to 125.21, p = 0.002), orbital cellulitis (OR, 320.54; 95% CI, 29.67 to 44801.64; p < 0.001), implant size (OR, 0.50; 95% CI, 0.30 to 0.79; p = 0.004), and hydroxyapatite for the implant (OR, 0.07; 95% CI, 0.00 to 0.66; p = 0.016) were risk factors for implant extrusion in univariate logistic regression analysis. Multiple logistic regression analysis identified orbital cellulitis as the only risk factor for extrusion (OR, 52.98; 95% CI, 2.18 to 15367.34; p = 0.009). Conclusions: Evisceration with primary orbital implantation is a feasible option in endophthalmitis, but the risk of extrusion should be taken into consideration. When performing evisceration in a patient with orbital cellulitis, secondary implantation should be carried out only after any infection is controlled.

scholarly journals Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0249435
Author(s):  
Shun-ichi Wakabayashi ◽  
Satoru Joshita ◽  
Kazuhiro Kimura ◽  
Hirohiko Motoki ◽  
Hiroyuki Kobayashi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Survival Rate ◽  
Chronic Liver Disease ◽  
Japanese Patients ◽  
The United States ◽  
Chronic Liver ◽  
University Hospital ◽  
Portopulmonary Hypertension ◽  
Japanese Adult ◽  
Real World Data

Background Portopulmonary hypertension (PoPH) is a subtype of the pulmonary arterial hypertension (PAH) associated with portal hypertension. There is a dissociation between the proportion of PoPH in PAH and that of PoPH in patients with liver cirrhosis, suggesting PoPH underdiagnosis and an incomplete understanding of this entity in the clinical setting. Specifically, real-world data in Japan is largely unknown as compared with in Europe and the United States. The present study aims to elucidate the prevalence and etiology of PoPH in Japanese patients with chronic liver disease. Methods and design In this prospective, single-center, observational investigation of PoPH patients with chronic liver disease, a targeted 2,500 Japanese adult patients regularly visiting Shinshu University Hospital in Matsumoto, Japan, for chronic liver disease will complete a standardized questionnaire on the presence of PoPH symptoms. If the respondent has signs of possible PoPH, ultrasound echocardiography (UCG) will be performed as a primary screening. In the case that UCG findings indicate pulmonary hypertension, the patient will be referred to a cardiologist for further evaluation, whereby a definitive diagnosis PoPH can be made. PoPH prevalence and etiology will be investigated at the time of diagnosis. Afterwards, patients with PoPH will be followed for five years for determination of survival rate. Discussion This study will reveal the prevalence, etiology, and 5-year survival rate of PoPH in Japanese patients with chronic liver disease. Trial registration This study is being performed at Shinshu University following registration as UMIN 000042287 on October 29, 2020.

Sign in / Sign up

Export Citation Format

Share Document